Status:
COMPLETED
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-small-cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best suppo...
Eligibility Criteria
Inclusion
- Stage IIIb (with effusion) or stage IV disease that has responded or remained stable after 6 cycles of a platinum containing 1st-line regimen
- Patients must be able to be randomized between 3 and no more than 6 weeks after the last dose of first-line therapy.
Exclusion
- No other systemic therapy except 1st-line platinum based treatment
- Symptomatic or uncontrolled brain mets or uncontrolled pleural effusions.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00312975
Start Date
May 1 2006
End Date
February 1 2010
Last Update
June 7 2012
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bentonville, Arkansas, United States, 72712
2
Research Site
Fayetteville, Arkansas, United States, 72703
3
Research Site
Orange, California, United States, 92868
4
Research Site
Danbury, Connecticut, United States, 06810